More articles from Commentary
- A world without Vioxx: To COX-2 or not to COX-2?
Are all selective COX-2 inhibitors associated with an increased risk for thromboembolic cardiovascular events? And what should we tell patients?
- It’s what’s inside the white coat that counts
Welcoming the first class of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
- Genetic discrimination arising from cancer risk assessments: A societal dilemma
The right to privacy of one’s most intimate biological secrets must be affirmed.
- The needs of science vs the needs of patients: Ethical concernsin cancer clinical trials
Patients in cancer trials are not data points; they are vulnerable people who often view a clinical trial as their last hope.
- Privacy protection for your patients: Understanding the federal requirements
On April 14, 2003, almost every medical provider in this country must implement new federal privacy rules. Here’s how.
- GUSTO V: Should it affect clinical practice?
The results of GUSTO V were equivocal and should not lead physicians to change how they treat myocardial infarction.
- The dangers of self-monitored dieting: What are our patients really doing?
Patient-monitored diets often leave questions of adherence and safety unanswered.
- C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging
CRP elevations are a sensitive test for inflammation, hut are not specific.
- In cholesterol lowering, moderation kills
The author’s experience indicates that a low-fat, plant-based diet can lower cholesterol to less than 150 mg/dL and reverse coronary artery disease.